A005690 Stock Overview
A biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Pharmicell Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩4,975.00 |
| 52 Week High | ₩8,870.00 |
| 52 Week Low | ₩4,300.00 |
| Beta | 0 |
| 11 Month Change | 1.43% |
| 3 Month Change | -17.08% |
| 1 Year Change | -22.63% |
| 33 Year Change | -62.31% |
| 5 Year Change | -36.54% |
| Change since IPO | 105.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| A005690 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 4.3% | -8.1% | 2.9% |
| 1Y | -22.6% | 18.1% | -2.8% |
Return vs Industry: A005690 underperformed the KR Biotechs industry which returned 18.1% over the past year.
Return vs Market: A005690 underperformed the KR Market which returned -2.8% over the past year.
Price Volatility
| A005690 volatility | |
|---|---|
| A005690 Average Weekly Movement | 5.3% |
| Biotechs Industry Average Movement | 8.1% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.6% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A005690 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A005690's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1968 | n/a | Hyun-Soo Kim | www.pharmicell.com |
Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to improve the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty.
Pharmicell Co., Ltd. Fundamentals Summary
| A005690 fundamental statistics | |
|---|---|
| Market cap | ₩287.42b |
| Earnings (TTM) | -₩26.78b |
| Revenue (TTM) | ₩23.94b |
0.0x
P/S Ratio0.0x
P/E RatioIs A005690 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A005690 income statement (TTM) | |
|---|---|
| Revenue | ₩23.94b |
| Cost of Revenue | ₩18.50b |
| Gross Profit | ₩5.45b |
| Other Expenses | ₩32.23b |
| Earnings | -₩26.78b |
Last Reported Earnings
Jun 30, 2014
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A005690 perform over the long term?
See historical performance and comparison